Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, Open Label, Dose Escalation and Expansion Study of RLY-1971, a Highly Potent and Selective SHP2 Inhibitor, in Subjects With Advanced or Metastatic Solid Tumors

NCT04252339 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT04252339
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04252339 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, Open Label, Dose Escalation and Expansion Study of RLY-1971, a Highly Potent and Selective SHP2 Inhibitor, in Subjects With Advanced or Metastatic Solid Tumors
Lead sponsor
Hoffmann-La Roche
Phase
Phase 1
Overall status
Completed
Start date
February 4, 2020
Completion date
November 22, 2022
Enrollment
56 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor, unspecified, adult